肝不全(Liver Failure)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Liver Failure Overview 7
Therapeutics Development 8
Pipeline Products for Liver Failure – Overview 8
Pipeline Products for Liver Failure – Comparative Analysis 9
Liver Failure – Therapeutics under Development by Companies 10
Liver Failure – Therapeutics under Investigation by Universities/Institutes 11
Liver Failure – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Liver Failure – Products under Development by Companies 15
Liver Failure – Products under Investigation by Universities/Institutes 16
Liver Failure – Companies Involved in Therapeutics Development 17
Alfact Innovation 17
Conatus Pharmaceuticals Inc. 18
Digna Biotech, S.L. 19
Grifols, S.A. 20
Immune Pharmaceuticals, Ltd. 21
Ventria Bioscience 22
Liver Failure – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
albumin (human) – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ALF-5755 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BI-78D3 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cardiotrophin-1 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy for Liver Failure – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
emricasan – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
F-573 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ImmuneSafe – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Oligonucleotide for Liver Failure – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Recombinant Protein for Liver Failure – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Recombinant Protein to Inhibit JNK for Liver Failure – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Activate Glutathione Peroxidase for Ischemic Stroke and Liver Failure – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Stem Cell Therapy for Liver Failure – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
VEN-100 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Liver Failure – Recent Pipeline Updates 51
Liver Failure – Dormant Projects 56
Liver Failure – Product Development Milestones 57
Featured News & Press Releases 57
Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 57
Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 59
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan’s Safety Profile at the AASLD Liver Meeting 59
Apr 02, 2013: ALF-5755 phase II completion 60
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 60
Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment 61
May 06, 2011: ALF-5755 phase II extends to germany 62
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 62
Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I 62
Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65